查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球产后出血治疗市场 - 2023-2030
市场调查报告书
商品编码
1352180

全球产后出血治疗市场 - 2023-2030

Global Postpartum Hemorrhage Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

由于技术进步和研究人员之间的合作不断增加，产后出血治疗市场趋势显示研究不断增加。全球孕产妇死亡的最大原因是产后出血（PPH），其定义为分娩后 24 小时内出血超过 500 毫升。

它每年影响约 1,400 万名妇女，造成超过 7 万人死亡，其中大多数发生在低收入和中等收入国家，根据世界卫生组织的数据，每六分钟就有一人死亡。此外，由于核准技术的不断增加以及市场上与产后出血相关的死亡人数的增加，产后出血治疗方法的增加正在推动产后出血治疗市场规模的扩大。

由于该领域的不断进步，北美市场对治疗的需求正在增长。由于 Teleflex Incorporated、Cook、Utah Medical Products, Inc 和 Organon 集团等重要竞争对手在市场上积极运营，市场将在未来一段时间内成长。

动力学

研究组织不断增长的研究和开发推动了产后出血治疗市场的成长

产后出血治疗技术目前广泛应用于分子医学，特别是生物标记的鑑定。根据伯明翰大学和世界卫生组织 (WHO) 研究人员发布的一项具有里程碑意义的研究，一种名为 E-MOTIVE 的新方法可以显着降低分娩相关出血引起的死亡率。

建议的 E-MOTIVE 套件包含一个采血巾，用于早期、精确检测 PPH。当有需要时，也会添加紧急治疗方案，包括子宫按摩、压迫子宫和止血的药物、静脉输液、评估，以及在必要时升级至高级护理。

实施计划包括专门培训、产后出血手推车或手提箱、争取当地冠军的帮助、审核和回馈，用于支持实验期间的 E-MOTIVE 干预。助产士可以完成 E-MOTIVE 干预的每一步。由于大量研究，预计市场将在整个预测期内处于领先地位。

政府或非政府组织不断增加的策略性倡议为市场成长创造了机会

国际妇产科联合会（FIGO）正在积极支持降低全球孕产妇死亡率和残疾率的努力。其目标声明体现了致力于促进所有妇女的健康、人权和福祉，特别是那些因生育而面临最大死亡或残疾风险的妇女。在获得知情许可的情况下使用，FIGO 的循证干预措施可以降低孕产妇患病的频率和死亡率。

在高收入国家，多模式技术已被用于管理产后出血等死亡率较高的疾病。这些措施由一系列干预措施以及建立并彻底解决各种病理管理问题的多学科计划的实施组成，其中涉及许多干预点和参与者，称为「捆绑」或干预包。捆绑包提供了一系列现有的建议和指南，以促进系统化实施和实践统一。

当每个组成部分都高度遵守时，FIGO 相信捆绑护理策略可以改善患者的治疗效果。可以使用的捆绑包有很多，每个卫生系统都需要采用一种。将捆绑包放置在每家妇产科医院中，并为其所有组件提供培训，从患者到达产科直到他们被转移到更高级别的护理。

与治疗相关的副作用将阻碍市场的成长

抽搐（癫痫发作）、精神错乱、呼吸问题、心跳加快或不规则、头晕、严重或持续性头痛、荨麻疹、皮疹或搔痒、严重骨盆或腹部疼痛、阴道出血增加或持续、体重快速增加和虚弱。很少有可能会或可能不会出现的副作用。

服用过量的症状包括颤抖、烦躁、疲倦、言语不清、反应迟缓和意识不清。有某些潜在的副作用，通常不需要治疗。随着身体习惯药物，这些副作用可能会在治疗期间消失。这些因素会限制市场的扩张。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按类型分類的片段
  • 治疗片段
  • 按销售管道分類的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 研究组织不断加强研究与开发
      • 不断进步的技术
    • 限制
      • 与治疗相关的副作用
    • 机会
      • 政府或非政府组织不断提出的策略性倡议
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情况
    • COVID-19 期间的情况
    • COVID-19 后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按类型

  • 原发性产后出血
  • 继发性产后出血

第 8 章：透过治疗

  • 药物
    • 催产素（催产素）
    • 卡前列素氨丁三醇（欣母沛）
    • 马来酸甲基麦角新碱（Methergine）
    • 米索前列醇（Cytotec）
    • 地诺前列酮（Prostin E2）
    • 传明酸（Cyklokapron）
  • 装置
    • 子宫填塞装置
      • 福利导管
      • 保险套导尿管
      • Bakri Temponade 气球
    • 非气动防震服
    • 预灌封注射系统

第 9 章：按销售管道

  • 配销通路
    • 医院药房
    • 零售药局
    • 网路药局
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Teleflex Incorporated
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Cook
  • Utah Medical Products, Inc.
  • OBSTETRX
  • BACTIGUARD AB
  • Organon group of companies
  • 3rd Stone Design
  • Pfizer Inc.
  • American Regent, Inc.
  • Ferring BV

第 13 章：附录

简介目录
Product Code: PH6948

Overview

The postpartum hemorrhage treatment market trends show rising research owing to the rising technological advancements and collaborations among researchers. The biggest cause of maternal death globally is postpartum hemorrhage (PPH), which is defined as the bleeding of over 500 milliliters within 24 hours of giving delivery.

It affects approximately 14 million women annually and contributes to over 70 000 deaths, the most of which occur in low- and middle-income countries, or one every six minutes according to World Health Organization. Furthermore, rising treatments for postpartum hemorrhage due to the rising availability of approved technologies and increase in the number of deaths associated with post partum hemorrhage in the market is driving up the postpartum hemorrhage treatment market size.

The market is experiencing a growth in demand for treatment from North America as a result of the rising advancements in this field. With significant competitors like Teleflex Incorporated, Cook, Utah Medical Products, Inc., and Organon group of companies actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Research and Development by Research Organizations Drive the Growth of the Postpartum Hemorrhage Treatment Market

Postpartum hemorrhage treatment technology is currently widely applied in molecular medicine, particularly for the identification of biomarkers. According to a landmark study released by researchers from the University of Birmingham and the World Health Organization (WHO), a novel approach known as E-MOTIVE may significantly reduce mortality caused by childbirth-related bleeding.

The suggested E-MOTIVE kit comprises a blood-collection drape for the early and precise detection of PPH. An emergency treatment package that includes uterine massage, drugs to compress the womb and cease the bleeding, administering intravenous fluids, an assessment, and, if necessary, escalation to advanced care, is added to this when it is indicated.

An implementation plan that included specialized training, postpartum hemorrhage trolleys or carry cases, enlisting the help of local champions, audits, and feedback was used to support the E-MOTIVE intervention during the experiment. Midwives can complete every step of the E-MOTIVE intervention. The market is predicted to take the lead throughout the forecast period owing to high research studies.

Rising Strategic Initiatives by Government or Non-Government Organizations Creates Opportunities for the Growth of the Market

The International Federation of Gynecology and Obstetrics, or FIGO, is actively supporting efforts to lower maternal mortality and disability worldwide. Its goal statement reflects a dedication to advancing the health, human rights, and wellness of all women, particularly those who face the greatest risk of passing away or becoming disabled as a result of childbearing. When used with informed permission, FIGO's evidence-based interventions can lower the frequency of maternal illness and mortality.

In high-income countries, multimodal techniques have been used to manage diseases like PPH that have high mortality rates. The implementation of a number of interventions as well as multidisciplinary programs that establish and thoroughly address the management of a variety of pathologies make up these initiatives, which involve numerous intervention points and actors, known as "bundles" or intervention packages. Bundles provide a selection of already-existing recommendations and guidelines in a way that promotes systematized implementation and practice uniformity.

When there is high adherence to each component, FIGO believes the bundle care strategy can enhance patient outcomes. There are numerous bundles that can be used, and every health system needs to adopt one. Place the bundle in every maternity hospital and provide training for all of its components, from the time a patient arrives on the obstetrics department until the time they are transferred to higher level care.

The Side Effects Associated with Treatment will hamper the growth of the market

Convulsions (seizures), confusion, breathing issues, a fast or irregular heartbeat, dizziness, severe or persistent headaches, hives, skin rashes or itching, severe pelvic or abdominal pain, increased or persistent vaginal bleeding, rapid weight gain, and weakness are a few side effects that may or may not manifest.

Overdose symptoms include trembling, restlessness, tiredness, slurred speech, sluggish response times, and unconsciousness. There are certain potential side effects that often do not require medical treatment. As the body gets used to the medication, these side effects could go away during treatment. These elements can limit the market's expansion.

Segment Analysis

The global postpartum hemorrhage treatment market is segmented based type, treatment, sales channel and region.

Owing to High Adoption, the Oxytocin (Pitocin) from Treatment Segment Accounted for Approximately 43.2% of the Postpartum Hemorrhage Treatment Market Share

The oxytocin (Pitocin) category from treatment held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a high demend and its high efficacy worldwide. By encouraging the generation of prostaglandins and raising the intracellular calcium ion concentrations in myometrial cells, oxytocin, which is produced by the posterior pituitary, causes an increase in uterine contractions. The upper myometrial segment undergoes regular contractions, which restrict spiral arteries and lessen uterine blood flow.

Individual differences in the amount of myometrial oxytocin receptors affect both the sensitivity and reaction of the uterus to the injection of oxytocin. Oxytocin is produced synthetically to lower the possibility of contamination from vasopressin and additional biologically active peptides. Only after the anterior shoulder delivery is oxytocin given. Oxytocin has a plasma half-life of 1 to 6 minutes. Oxytocin IV patients experience an instantaneous uterine response that lasts for about 60 minutes. In 3 to 5 minutes after administering IM oxytocin, patients experience a 2 to 3 hour long uterine response.

There is currently no dose regimen that has been demonstrated to have greater results than another. The highest oxytocin cumulative dose that is advised is 40 units. Single-dose 1-mL vials of oxytocin and multidose 10-mL vials, both containing 10 units/mL, are available. Vials must be kept at room temperature for storage.

Geographical Penetration

North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for postpartum hemorrhage medication in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for treatment for postpartum hemorrhage.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment purpose, and increase in pharmaceutical and women health business establishment across the region are also contributing to the growth of postpartum hemorrhage treatment market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various technologies and treatment for postpartum hemorrhage that are being utilized for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the postpartum hemorrhage treatment market include Teleflex Incorporated, Cook, Utah Medical Products, Inc., OBSTETRX, BACTIGUARD AB, Organon group of companies, 3rd Stone Design, Pfizer Inc., American Regent, Inc. and Ferring B.V. among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide postpartum hemorrhage treatment market. The growth of the global postpartum hemorrhage treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

  • Primary Postpartum Hemorrhage
  • Secondary Postpartum Hemorrhage

By Treatment

  • Medications
    • Oxytocin (Pitocin)
    • Carboprost Tromethamine (Hemabate)
    • Methylergonovine Maleate (Methergine)
    • Misoprostol (Cytotec)
    • Dinoprostone (Prostin E2)
    • Tranexamic Acid (Cyklokapron)
  • Devices
    • Uterine Tamponade Devices
      • Foley Catheter
      • Condom Catheter
      • Bakri Temponade Balloon
  • Non-Pneumatic Anti-Shock Garment
  • Prefilled Injection System

By Sales Channel

  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On January 10, 2023, following a thorough authorization procedure, Bactiguard announces the approval of its first Medical Device Regulations (MDR) product. The latex BIP Foley Catheter, an indwelling urinary catheter featuring Bactiguard's exclusive infection prevention technology, is the subject of the MDR approval.
  • On October 11, 2021, the U.S. Food and Drug Administration (FDA) has approved the Special 510(k) for technical changes to the Jada System, which is designed to control and treat abnormal Postpartum Hemorrhage Treatment or uterine bleeding when conservative management is necessary, according to Organon, a global women's health company.
  • On July 26, 2021, After nearly ten years of public-private cooperation, Ferring Pharmaceuticals announced the first application of heat-stable carbetocin (Carbetocin Ferring) to stop excessive Postpartum Hemorrhage Treatment (PPH). It is now possible to employ heat-stable carbetocin in hospitals all throughout India to stop excessive bleeding after vaginal and cesarean deliveries.

DMI Opinion:

The global postpartum hemorrhage treatment market is going to see decent growth in upcoming years owing to rising usage of postpartum hemorrhage medication and novel technologies or devices that are being developed. Several researches are taking place worldwide to enhance the management of postpartum hemorrhage. Numerous advances are taking place leading to the growth of market such as uterine tempons or drapes. According to DMI the postpartum hemorrhage treatment market will see a decent growth with several novel treatments in the market.

Why Purchase the Report?

  • To visualize the global postpartum hemorrhage treatment market segmentation based on type, treatment, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of postpartum hemorrhage treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global postpartum hemorrhage treatment market report would provide approximately 62 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Sales Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development by Research Organizations
      • 4.1.1.2. Rising Technological Adavancements
    • 4.1.2. Restraints
      • 4.1.2.1. The Side Effects Associated with Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Strategic Initiatives by Government or Non-Government Organizations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Primary Postpartum Hemorrhage *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Secondary Postpartum Hemorrhage

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Medications *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Oxytocin (Pitocin)
    • 8.2.4. Carboprost Tromethamine (Hemabate)
    • 8.2.5. Methylergonovine Maleate (Methergine)
    • 8.2.6. Misoprostol (Cytotec)
    • 8.2.7. Dinoprostone (Prostin E2)
    • 8.2.8. Tranexamic Acid (Cyklokapron)
  • 8.3. Devices
    • 8.3.1. Uterine Tamponade Devices
      • 8.3.1.1. Foley Catheter
      • 8.3.1.2. Condom Catheter
      • 8.3.1.3. Bakri Temponade Balloon
    • 8.3.2. Non-Pneumatic Anti-Shock Garment
    • 8.3.3. Prefilled Injection System

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.1.2. Market Attractiveness Index, By Sales Channel
  • 9.2. Distribution Channel *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Hospital Pharmacies
    • 9.2.4. Retail Pharmacies
    • 9.2.5. Online Pharmacies
  • 9.3. End User
    • 9.3.1. Hospitals
    • 9.3.2. Ambulatory Surgical Centers
    • 9.3.3. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.4.1. Brazil
      • 12.4.4.2. Argentina
      • 12.4.4.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teleflex Incorporated *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Cook
  • 12.3. Utah Medical Products, Inc.
  • 12.4. OBSTETRX
  • 12.5. BACTIGUARD AB
  • 12.6. Organon group of companies
  • 12.7. 3rd Stone Design
  • 12.8. Pfizer Inc.
  • 12.9. American Regent, Inc.
  • 12.10. Ferring B.V.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us